ASH

Ashland is a global specialty-additives company (Life Sciences, Personal Care, Specialty Additives, Intermediates; 73% of FY2025 sales outside North America) whose top line is in a clear multi-year contraction. Revenue has fallen every year from the FY2022 peak of $2.39B to $1.82B in FY2025, and the decline accelerated to -13.7% last year. FY2025 produced a -$845M net loss and a -$775M operating loss (YoY -2,881%), but operating cash flow stayed positive at $134M — the gap tells you the loss is dominated by a large non-cash impairment, not an operating cash bleed. That is the one genuinely reassuring fact here: the company is not burning cash. But an ~$800M write-down is management formally marking down the value of acquired businesses, and that reflects real, not cosmetic, value destruction layered on top of a shrinking revenue base and a gross margin that, while still 30.1%, slipped again.

The balance sheet is the floor under the stock and the reason this is a 'sell' rather than an 'avoid.' Equity is still $1.90B even after the impairment, current assets of $1.21B cover current liabilities of $423M nearly 3x, and there is no current portion of debt against $1.38B of long-term debt and $215M of cash — no near-term solvency risk. The problem for the equity is capital allocation against a declining business: Ashland paid $76M in dividends and $100M in buybacks in FY2025 ($176M of returns) while free cash flow (OCF $134M less capex $98M) was only ~$36M. Returning roughly 5x your free cash flow by drawing on the balance sheet is not sustainable if revenue keeps falling, and ROE of -44.4% and retained earnings down 30.7% show the erosion is already hitting book value.